Ligand-directed targeting of genes to the site of disease

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 135-139

  Wickham, Thomas J ^a  

^a GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DIPEPTIDYL CARBOXYPEPTIDASE; LIGAND; MACROGOL; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYETHYLENEIMINE; POLYMER; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; CELL TRANSPORT; COVALENT BOND; DNA VECTOR; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TRANSPORT; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; GLAUCOMA; HEARING LOSS; IMMUNITY; LIGAND BINDING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR SENSITIVITY; REVIEW; SINDBIS VIRUS; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIGANDS; RETROVIRIDAE;

ADENOVIRIDAE; SINDBIS VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0037231625     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0103-135     Document Type: Review

References (69)

1. Curiel, D.T. & Douglas, J.T. (eds). Vector Targeting for Therapeutic Gene Delivery, 710 (Wiley-Liss, Hoboken, NJ, 2002).
2. Bilbao, R. et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther. 7, 1824-1832 (2000).
3. Shayakhmetov, D.M., Li, Z.Y., Ni, S. & Lieber, A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 62, 1063-1068 (2002).
4. Tomko, R.P., Xu, R. & Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94, 3352-3356 (1997).
5. Bergelson, J.M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323 (1997).
6. Wickham, T.J., Mathias, P., Cheresh, D.A. & Nemerow, G.R. Integrins αvβ3 and αcβ5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319 (1993).
7. Einfeld, D.A. et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75, 11284-11291 (2001).
8. Thomas, C.E., Edwards, P., Wickham, T.J., Castro, M.G. & Lowenstein, P.R. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J. Virol. 76, 3452-3460 (2002).
9. Michael, S.I., Hong, J.S., Curiel, D.T. & Engler, J.A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 2, 660-668 (1995).
10. Wickham, T.J. et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229 (1997).
11. Einfeld, D.A., Brough, D.E., Roelvink, P.W., Kovesdi, I. & Wickham, T.J. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 73, 9130-9136 (1999).
12. Vigne, E. et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 73, 5156-5161 (1999).
13. Yang, Q. et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 9, 1929-1937 (1998).
14. Wickham, T.J. Targeting adenovirus. Gene Ther. 7, 110-114 (2000).
15. Bartlett, J.S., Kleinschmidt, J., Boucher, R.C. & Samulski, R.J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′τ)2 antibody. Nature Biotechnol. 17, 181-186 (1999).
16. Boerger, A.L., Snitkovsky, S. & Young, J.A. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc. Natl. Acad. Sci. USA 96, 9867-9872 (1999).
17. Snitkovsky, S., Niederman, T.M., Carter, B.S., Mulligan, R.C. & Young, J.A. A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor. J. Virol. 74, 9540-9545 (2000).
18. Snitkovsky, S., Niederman, T.M, Mulligan, R.C. & Young, J.A. Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein. J. Virol. 75, 1571-1575 (2001).
19. Snitkovsky, S. & Young, J.A. Targeting retroviral vector infection to cells that express heregulin receptors using a TVA-heregulin bridge protein. Virology 292, 150-155 (2002).
20. Ohno, K., Sawai, K., lijima, Y., Levin, B. & Meruelo, D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nature Biotechnol. 15, 763-767 (1997).
21. Dmitriev, I., Kashentseva, E., Rogers, B.E., Krasnykh, V. & Curiel, D.T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74, 6875-6884 (2000).
22. Douglas, J.T. et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnol. 14, 1574-1578 (1996).
23. Kim, J. et al. Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J. Virol. 76, 1892-1903 (2002).
24. Hood, J.D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407 (2002).
25. Nettelbeck, D.M. et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol. Ther. 3, 882-891 (2001).
26. Harari, O.A. et al. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther. 6, 801-807 (1999).
27. Wickham, T.J., Haskard, D., Segal, D. & Kovesdi, I. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol. Immunother. 45, 149-151 (1997).
28. Heideman, D.A. et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther. 8, 342-351 (2001).
29. Reynolds, P.N. et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Biotechnol. 19, 838-842 (2001).
30. Dingli, D. & Russell, S.J. Genetic targeting of retroviral vectors. in Vector Targeting for Therapeutic Gene Delivery (eds. Curiel, D.T. & Douglas, J.T.) 267-291 (Wiley-Liss, Hoboken, NJ, 2002).
31. Russell, S.J., Hawkins, R.E. & Winter, G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21, 1081-1085 (1993).
32. Kasahara, N., Dozy, A.M. & Kan, Y.W. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376 (1994).
33. Cosset, F.L. et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314-6322 (1995).
34. Valsesia-Wittmann, S. et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68, 4609-4619 (1994).
35. Hatziioannou, T., Delahaye, E., Martin, F., Russell, S.J. & Cosset, F.L. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum. Gene Ther. 10, 1533-1544 (1999).
36. Morling, F.J., Peng, K.W., Cosset, F.L. & Russell, S.J. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 234, 51-61 (1997).
37. Peng, K.W., Vile, R., Cosset, F.L. & Russell, S. Selective transduction of proteaserich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 6, 1552-1557 (1999).
38. Peng, K.W., Morling, F.J., Cosset, F.L., Murphy, G. & Russell, S.J. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene Ther. 8, 729-738 (1997).
39. Gordon, E.M. et al. Lesion-targeted injectable vectors for vascular restenosis. Hum. Gene Ther. 12, 1277-1287 (2001).
40. Gordon, E.M. et al. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum. Gene Ther. 12, 193-204 (2001).
41. Hall, F.L. et at. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum. Gene Ther. 8, 2183-2192 (1997).
42. Hall, F.L. et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum. Gene Ther. 11, 983-993 (2000).
43. Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adenoassociated virus type 2. Nature Med. 5, 1052-1056 (1999).
44. Grifman, M. et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975 (2001).
45. Nicklin, S.A. et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174-181 (2001).
46. Ried, M.U., Girod, A., Leike, K., Buning, H. & Hallek, M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J. Virol. 76, 4559-4566 (2002).
47. Hammond, A.L. et al. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 75, 2087-2096 (2001).
48. Xiang, Z. et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76, 2667-2675 (2002).
49. Croyle, M.A., Chirmule, N., Zhang, Y. & Wilson, J.M. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-4801 (2001).
50. Croyle, M.A., Yu, Q.C. & Wilson, J.M. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11, 1713-1722 (2000).
51. Fisher, K.D. et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341-348 (2001).
52. Romanczuk, H. et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum. Gene Ther. 10, 2615-2626 (1999).
53. Ogris, M. & Wagner, E. Targeting tumors with non-viral gene delivery systems. Drug Discov. Today 7, 479-485 (2002).
54. MacLachlan, I., Cullis, P. & Graham, R.W. Progress towards a synthetic virus for systemic gene therapy. Curr. Opin. Mol. Ther. 1, 252-259 (1999).
55. Kircheis, R. et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8, 28-40 (2001).
56. Xu, L., Pirollo, K.F., Tang, W.H., Rait, A. & Chang, E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 10, 2941-2952 (1999).
57. Fenske, D.B., MacLachlan, I. & Cullis, P.R. Long-circulating vectors for the systemic delivery of genes. Curr. Opin. Mol. Ther. 3, 153-158 (2001).
58. Kircheis, R., Wightman, L. & Wagner, E. Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 53, 341-358 (2001).
59. Kircheis, R. et al. Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther. 9, 673-680 (2002).
60. Ogris, M., Brunner, S., Schuller, S., Kircheis, R. & Wagner, E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595-605 (1999).
61. LeVine, A.M. & Whitsett, J.A. Pulmonary collectins and innate host defense of the lung. Microbes Infect. 3, 161-166 (2001).
62. Malhotra, R. & Sim, R.B. Collectins and viral infection. Trends Microbiol. 3, 240-244 (1995).
63. Reading, P.C., Holmskov, U. & Anders, E.M. Antiviral activity of bovine collectins against rotaviruses. J. Gen. Virol. 79, 2255-2263 (1998).
64. Reading, P.C., Morey, L.S., Crouch, E.C. & Anders, E.M. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J. Virol. 71, 8204-8212 (1997).
65. St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).
66. Pereboev, A., Pereboeva, L. & Curiel, D.T. Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation. J. Virol. 75, 7107-7113 (2001).
67. Engelstadter, M. et al. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum. Gene Ther. 11, 293-303 (2000).
68. Buchholz, C.J. et al. In vivo selection of protease cleavage sites from retrovirus display libraries. Nature Biotechnol. 16, 951-954 (1998).
69. Gordon, E.M., Hall, F.L., Beart, R.W. & Anderson, W.F. Genetic engineering of targeted retroviral vectors. in Vector Targeting for Therapeutic Gene Delivery (eds. Curiel, D.T. & Douglas, J.T.) 293-320 (Wiley-Liss, Hoboken, NJ, 2002).